Computed Tomography in Chronic Pancreatitis

Author(s):  
W. Maier
Author(s):  
Han-Yue Wang ◽  
◽  
Hao-Su Huang ◽  
Meng Wang ◽  
Jie Peng ◽  
...  

Background: Mass-Forming Chronic Pancreatitis (MFCP) is rare. Moreover, atypical MFCP is difficult to differentiate from Pancreatic Carcinoma (PC) in clinical manifestations, laboratory, and imaging examinations. Diagnosis could be supported by the pathological findings of focal inflammatory fibrosis without evidence of tumor in the pancreas. Case summary: A 52-year-old man had acute pancreatitis twice over 7 months. Amylase and lipase levels were three times higher than the normal range without any clinical symptoms. At the 6th month, the patient lost 15 kg of weight, and abdominal ultrasonography revealed pancreatic head space occupied. All the findings in multimodal imaging including computed tomography image, Magnetic Resonance (MR) imaging with MR cholangiopancreatography, and 18F-FDG positron emission tomography/computed tomography showed an irregular nodule with low density, low signal, and low echo in the head of the pancreas, which were lower than those in the normal pancreatic tissue. The proximal main pancreatic duct was truncated and stenosed, and the distal duct was dilated. Subsequently, he developed progressive painless jaundice, and the specific tumor marker levels were increased. Most of these manifestations were suggestive of the pancreatic malignant tumor; however, multiple specimen pathological findings obtained from laparotomy and endoscopic ultrasonography-guided fine-needle aspiration revealed focal chronic inflammation, fibrosis, and necrosis. Conclusion: This report describes a case of atypical MFCP mimicking PC at clinical presentation and laboratory findings, especially in multimodal imaging. However, the combination of atypical multimodal imaging features, which support MFCP rather than PC, and endoscopic ultrasonography-guided fine-needle aspiration are useful for improving the diagnostic rate of atypical MFCP and avoiding unnecessary surgery.


2019 ◽  
Vol 44 (7) ◽  
pp. 2459-2465 ◽  
Author(s):  
Ahmed Abdel Khalek Abdel Razek ◽  
Elsayed Elfar ◽  
Shefeek Abubacker

2021 ◽  
Vol 10 (11) ◽  
pp. 819-824
Author(s):  
Sharvari Shashikant Gulve ◽  
Pratapsingh Hanumantsingh Parihar ◽  
Rajasbala Pradeep Dhande

BACKGROUND Pancreatic lesions range from inflammation to malignancy and are associated with high morbidity and mortality. Imaging pancreatic lesion is challenging as pancreas is located retroperitoneally and with close proximity to bowel and major blood vessels. Abdominal pain, vomiting, and nausea are commonly reported symptoms. They are associated with high morbidity. Multi detector computed tomography (MDCT) is the modality of choice for detecting pancreatic pathology. It is highly sensitive in detecting necrosis, pancreatitis, peripancreatic fluid collections, calcification, neoplasm, pancreatic enlargement, atrophy and cystic lesions of pancreas. Computed tomography (CT) scan has made it possible to identify and detect various benign and malignant pancreatic lesions. METHODS A prospective observational study of 180 patients with complaints suggestive of pancreatic disease was done based on clinical, laboratory and ultrasonography in the Department of Radiodiagnosis, Acharya Vinoba Bhave Rural Hospital, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe). Siemens Somatom 16 slice CT scan machine was used. All 180 patients underwent plain and contrast enhanced CT scan. RESULTS Out of 180 study participants 105 (58.33 %) were with acute pancreatitis followed by 43 (23.89 %) with chronic pancreatitis, 21 (11.67 %) with acute exacerbation of chronic pancreatitis, 10 (5.56 %) participants with carcinoma pancreas and 1 (0.56 %) participant with pancreatic injury participated in the study. CONCLUSIONS Contrast enhanced computed tomography (CECT) is an excellent diagnostic modality to stage severity of inflammatory process, staging of neoplastic lesions and traumatic injury. It is most accurate and affordable non-invasive imaging modality for the evaluation of pancreatic lesions. It is a standard investigation to identify and quantify distribution of various pancreatic lesions and also evaluates activeness and progression of disease. Thus, it helps in accurate diagnosis and characterization of lesion and in proper treatment of patients. KEY WORDS Pancreas, Imaging, Computed Tomography


2018 ◽  
Vol 22 (7) ◽  
pp. 1-114 ◽  
Author(s):  
Paula Ghaneh ◽  
Robert Hanson ◽  
Andrew Titman ◽  
Gill Lancaster ◽  
Catrin Plumpton ◽  
...  

Background Pancreatic cancer diagnosis and staging can be difficult in 10–20% of patients. Positron emission tomography (PET)/computed tomography (CT) adds precise anatomical localisation to functional data. The use of PET/CT may add further value to the diagnosis and staging of pancreatic cancer. Objective To determine the incremental diagnostic accuracy and impact of PET/CT in addition to standard diagnostic work-up in patients with suspected pancreatic cancer. Design A multicentre prospective diagnostic accuracy and clinical value study of PET/CT in suspected pancreatic malignancy. Participants Patients with suspected pancreatic malignancy. Interventions All patients to undergo PET/CT following standard diagnostic work-up. Main outcome measures The primary outcome was the incremental diagnostic value of PET/CT in addition to standard diagnostic work-up with multidetector computed tomography (MDCT). Secondary outcomes were (1) changes in patients’ diagnosis, staging and management as a result of PET/CT; (2) changes in the costs and effectiveness of patient management as a result of PET/CT; (3) the incremental diagnostic value of PET/CT in chronic pancreatitis; (4) the identification of groups of patients who would benefit most from PET/CT; and (5) the incremental diagnostic value of PET/CT in other pancreatic tumours. Results Between 2011 and 2013, 589 patients with suspected pancreatic cancer underwent MDCT and PET/CT, with 550 patients having complete data and in-range PET/CT. Sensitivity and specificity for the diagnosis of pancreatic cancer were 88.5% and 70.6%, respectively, for MDCT and 92.7% and 75.8%, respectively, for PET/CT. The maximum standardised uptake value (SUVmax.) for a pancreatic cancer diagnosis was 7.5. PET/CT demonstrated a significant improvement in relative sensitivity (p = 0.01) and specificity (p = 0.023) compared with MDCT. Incremental likelihood ratios demonstrated that PET/CT significantly improved diagnostic accuracy in all scenarios (p < 0.0002). PET/CT correctly changed the staging of pancreatic cancer in 56 patients (p = 0.001). PET/CT influenced management in 250 (45%) patients. PET/CT stopped resection in 58 (20%) patients who were due to have surgery. The benefit of PET/CT was limited in patients with chronic pancreatitis or other pancreatic tumours. PET/CT was associated with a gain in quality-adjusted life-years of 0.0157 (95% confidence interval –0.0101 to 0.0430). In the base-case model PET/CT was seen to dominate MDCT alone and is thus highly likely to be cost-effective for the UK NHS. PET/CT was seen to be most cost-effective for the subgroup of patients with suspected pancreatic cancer who were thought to be resectable. Conclusion PET/CT provided a significant incremental diagnostic benefit in the diagnosis of pancreatic cancer and significantly influenced the staging and management of patients. PET/CT had limited utility in chronic pancreatitis and other pancreatic tumours. PET/CT is likely to be cost-effective at current reimbursement rates for PET/CT to the UK NHS. This was not a randomised controlled trial and therefore we do not have any information from patients who would have undergone MDCT only for comparison. In addition, there were issues in estimating costs for PET/CT. Future work should evaluate the role of PET/CT in intraductal papillary mucinous neoplasm and prognosis and response to therapy in patients with pancreatic cancer. Study registration Current Controlled Trials ISRCTN73852054 and UKCRN 8166. Funding The National Institute for Health Research Health Technology Assessment programme.


Sign in / Sign up

Export Citation Format

Share Document